BGM0504 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
BGM0504 is a drug built from tirzepatide. In a mid-stage study of 64 people, it lowered average blood sugar and weight more than semaglutide 1 mg. Its large final-stage weight-loss result, often quoted as 19.3 percent, exists only as a company press release. It has not been published.
Evidence grade for BGM0504: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, 64 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 64
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 64 people given it
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Fat loss and metabolism, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
BGM0504 is a weekly shot from China built from tirzepatide, the drug in Mounjaro. It works on the same two hunger and blood sugar signals. It is not approved anywhere. The biggest number you will see for it comes from a press release, not a published study.
What people take it for
- Weight loss.
- Lower blood sugar in type 2 diabetes.
- The hope that it is stronger than tirzepatide.
What studies in people showed
Only 104 people have been in published studies. In 64 adults with type 2 diabetes, the top dose cut average blood sugar by 2.48 points in 12 weeks. Semaglutide cut it by 1.43. But each group had just 12 people. In 40 healthy people, weight fell 3.24 to 8.30 percent over a short time. The company says a big final study found 19.3 percent weight loss. That study is not published, so nobody can check it. In a dish, it was two to three times as strong as tirzepatide. That does not mean it works better in people.
What people report
Reports, not study results
The good
- In one small study, the top dose lowered blood sugar and weight more than semaglutide.
- The company says only 0.7 percent quit on the high dose in its unpublished study.
The bad
- Vomiting, nausea, less hunger, diarrhoea and bloating were the most common side effects.
- The big weight-loss claim is unpublished and cannot be checked.
- Anything sold online under this code is not what was in the studies.
Where these come from: The published studies on this page and the company press release. We have not collected user reports on this one yet.
My bottom line
Wait for the published paper. A press release is a sales pitch until outside experts check it. And do not buy research vials with this name on them.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals BGM0504 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weight104 people · 2 studies
- Blood sugar and insulin64 people · 1 study
- Feeling less hungry40 people · 1 study
- Gut and digestion40 people · 1 study
32 of the 36 indexed goals have no study of any kind behind BGM0504
No study in people, animals or cells on this page reports a result for these. That does not prove BGM0504 does nothing for them. It does mean anything you have heard about BGM0504 and one of these did not come from a study cited here.
Show full evidence
What is BGM0504?
BGM0504 is a drug built from tirzepatide. In a mid-stage study of 64 people, it lowered average blood sugar and weight more than semaglutide 1 mg. Its large final-stage weight-loss result, often quoted as 19.3 percent, exists only as a company press release. It has not been published.
BGM0504 comes from BrightGene Bio-Medical in Suzhou. It is openly built from tirzepatide, and the design paper says so. Computer models found a spot where the parent drug locks onto both of its target switches. The team moved the drug's fatty chain to protect that spot. In a dish, the new drug was two to three times as strong as tirzepatide at switching on its targets, and it still lasted a long time in the blood.
That is real protein engineering, published in a reviewed journal. But it is a strength claim from cells and animals. A stronger result in a dish is not a result in people.
The human data published so far is small. There is an early safety study in 40 healthy volunteers. There is a mid-stage study in 64 Chinese adults with type 2 diabetes. In that study the 15 mg dose lowered average blood sugar (HbA1c) by 2.48 points, against 1.43 for semaglutide 1 mg. It also took off more weight than semaglutide. With 12 people per group, those are early signs. The authors use exactly that word, a signal.
The large final-stage study is where it gets awkward. In May 2026 the company announced by press release that its weight-loss study hit its main goal. It reported 19.3 percent average weight loss, a waist 16.5 cm smaller, better blood pressure and uric acid, and only 0.7 percent of people quitting on the high dose. At the time of this review, none of that had been published in a reviewed journal. It is a company statement about its own unpublished study. It is also the number every other source quotes.
BrightGene also has a separate long-acting drug, BGM1812, which has its own page on this site.
How does BGM0504 work?
It works on two gut hormone switches, GLP-1 and GIP. That is the same pair tirzepatide works on, and the drug is built from tirzepatide. The designers used computer models to find a spot where the parent drug locks onto both switches. That spot did not show up in the usual 3D pictures of the molecules. They then moved the drug's fatty chain so it would not get in the way. In a dish, the result was two to three times as strong as tirzepatide, and it still lasted long in the blood. The GLP-1 switch cuts appetite and helps control blood sugar. What the GIP switch adds to weight loss is still argued over. Drugs that switch it on and drugs that block it are both in development.
What have studies in people found about BGM0504?
An early safety study in 40 volunteers and a mid-stage study in 64 people with type 2 diabetes, both published. A large final-stage weight-loss result was announced by press release in May 2026 and has not been published.
- Mid-stage study, 12 weeks, 12 people per BGM0504 group: average blood sugar (HbA1c) fell 2.48 points on 15 mg, against 1.43 on semaglutide 1 mg. The top dose also took off more weight.
- Early study in healthy volunteers: weight fell 3.24 to 8.30 percent across the doses over a short time. Blood levels rose in step with the dose.
- The company announced in May 2026 that its large final-stage weight-loss study hit its main goal, with 19.3 percent average weight loss and a waist 16.5 cm smaller. No published paper on that study was found for this review.
- Several large final-stage studies in type 2 diabetes and obesity are signing people up in China, and one in Indonesia. A pill version is in an early safety study.
What this does not tell you: The published human evidence adds up to 104 people across two studies. The longer one ran 12 weeks. The comparison that makes the drug interesting, against semaglutide, had 12 people per group. The design paper's main claim, two to three times as strong as tirzepatide, was measured in a dish. It has never been tested against tirzepatide in people. And the final-stage numbers going around are a company press release, not a published study.
The state of the research
This page exists partly to be clear about a line that gets blurred all the time in this field. There is a difference between a published study and an announced one.
The 19.3 percent weight-loss number comes from a press release by the company that makes the drug, about its own study. That study has not been checked by outside reviewers. How it was run, how dropouts were handled, how the result was calculated and the full list of side effects are not public. It may well hold up. Press-released final-stage results usually do. But until it is published, nobody outside the company can check how weight loss was worked out, who was left out, or how many people finished.
The published record is smaller and more modest. It is a 40-person early study and a 64-person mid-stage study whose authors call their own results a signal.
The dish result needs its own caution. Being two to three times as strong as tirzepatide on cells does not mean two to three times the effect in people, or any edge at all. Strength decides the dose, not the ceiling. Whether this drug does more than tirzepatide in people is untested, because no study has compared them.
One warning applies to every drug on this page. Chinese diabetes and weight drugs carry several names at once. There is a company code, a Chinese brand name, an official generic name given later, and sometimes a partner's code after a licensing deal. Those names rarely show up together in one place. So a search on the code may find only animal studies, while the human studies sit under the generic name, or the other way round. If a drug looks like it has thin evidence, check its other names first.
The evidence, in charts
Fig. 1a · how many people
104people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| Diabetes, Obesity and Metabolism 2026 | 64 | 62% |
| Diabetes, Obesity and Metabolism 2025 | 40 | 38% |
One study holds 62% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Lab (cells in a dish) · cells or tissue133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2024 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- An acylated dual agonist peptide derived from the tirzepatide scaffold. No mass is asserted here.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Long enough for once-weekly subcutaneous dosing, which the phase one pharmacokinetic profile was reported to support. No specific figure is asserted here.
No amino acid sequence is on file for BGM0504, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial
This is a twelve-people-per-group signal, and its authors call it that. 64 Chinese adults with type 2 diabetes took BGM0504 at 5, 10 or 15 mg, a dummy, or semaglutide, weekly for 12 weeks. Average blood sugar fell 1.72, 1.94 and 2.48 points on the three doses, against 1.43 on semaglutide and 0.28 higher on the dummy. The top dose took off more weight than semaglutide. Twelve people per group over twelve weeks cannot settle a comparison. Five authors work for BrightGene and may hold its stock.
64 Chinese adults with type 2 diabetes randomised to BGM0504 at 5, 10 or 15 mg, placebo, or semaglutide 1 mg, all weekly for 12 weeks. Mean glycated haemoglobin change was minus 1.72, minus 1.94 and minus 2.48 percentage points against minus 1.43 for semaglutide and plus 0.28 for placebo. The 15 mg dose showed greater weight reduction than semaglutide. The authors describe the findings as a signal throughout, which is appropriate for 12 participants per arm over 12 weeks. Five authors are BrightGene employees who may hold stock.
- Study in people2025The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study
Healthy volunteers, and the weight figures belong to healthy volunteers. 40 healthy Chinese people took a single 2.5 mg dose, then weekly doses rising to 5, 10 and 15 mg. The amount in the blood rose in step with the dose across that range. Weight fell 3.24, 6.26, 7.09 and 8.30 percent at the four doses. Vomiting, nausea, lost appetite, diarrhoea and bloating were the commonest complaints. These weight numbers come from healthy people over a short stretch, not from people with obesity being treated.
40 healthy Chinese volunteers, single 2.5 mg dose and weekly titration to 5, 10 and 15 mg. Maximum concentration and area under the curve were linearly proportional to dose across 2.5 to 15 mg, supporting weekly dosing. Body weight change from baseline was minus 3.24, minus 6.26, minus 7.09 and minus 8.30 percent at 2.5, 5, 10 and 15 mg. Gastrointestinal events, vomiting, nausea, decreased appetite, diarrhoea and abdominal distension, were the most frequent adverse events. These weight figures are from healthy volunteers over a short dosing period, not from people with obesity.
- Lab (cells in a dish)2024Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity
In a dish and in animals. The designers used computer models to find a spot where tirzepatide locks onto its two target switches. They moved the drug's fatty chain to protect that spot. The new drug was two to three times as strong as tirzepatide on cells, still lasted long in the blood, and did better than tirzepatide in animals. This is a design result. It says nothing about people.
The design paper. Molecular dynamics simulation identified a salt bridge between the tirzepatide parent peptide and both receptors at K20 that cryo-electron microscopy structures did not show, and the acylation side chain was repositioned accordingly. The optimised peptide showed a twofold to threefold increase in agonist activity over tirzepatide in vitro while retaining extended plasma half-life, and outperformed tirzepatide in animal studies. This is a potency and design result in cells and animals; it makes no clinical claim.
Where to buy BGM0504
No seller we track lists BGM0504 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has BGM0504 been tested in people?
Yes. 64 people given it across 1 completed trial cited here, 0 of which found nothing. BGM0504 is a drug built from tirzepatide. In a mid-stage study of 64 people, it lowered average blood sugar and weight more than semaglutide 1 mg. Its large final-stage weight-loss result, often quoted as 19.3 percent, exists only as a company press release. It has not been published.
What is the BGM0504 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 64 people given it
Is BGM0504 FDA-approved?
Not approved anywhere. Several final-stage studies are signing up patients in China and Indonesia, and a tablet version is in early safety studies. The final-stage obesity result announced in May 2026 had not been published in a checked medical journal when we reviewed it.
Is BGM0504 better than tirzepatide?
Nobody knows. No study has compared them. The claim that it is two to three times as strong comes from cell tests in the design paper. Being stronger in a dish decides the dose. It does not set how big the effect can get, and it does not show any real-world edge.
Where does the 19.3 percent weight loss number come from?
From a company press release in May 2026 saying the large final-stage weight-loss study hit its main goal. It has not been published in a reviewed journal. So nobody outside the company can check who was counted, how dropouts were handled, or the full list of side effects.
What does the published human evidence actually show?
An early study in 40 healthy volunteers, where blood levels rose in step with the dose and weight changed 3 to 8 percent over a short dose build-up. And a mid-stage study in 64 adults with type 2 diabetes. There, the 15 mg dose lowered average blood sugar 2.48 points, against 1.43 for semaglutide 1 mg, over 12 weeks. That is 104 people in total.
Can I buy it?
It is not approved in any country. Large final-stage studies are signing people up in China and Indonesia. Anything sold online under this code is not what was used in the studies. Nobody has checked what is in it or how pure it is.
Is it related to BGM1812?
Same company, different drug and different program. BGM1812 has its own page on this site.